Biotech and Pharmaceuticals
AstraZeneca Stock Slides as FDA Panel Rejects New Cancer Drug Proposal: What Does This Mean for Investors?
Shares of AstraZeneca dipped on Friday after U.S. regulators recommended against its new cancer drug. The FDA advisory committee voted ... Read more
Intellia Therapeutics’ CRISPR Breakthrough: Pivotal Trial Confirms Successful Treatment Results
Intellia Therapeutics is making waves in the world of gene editing. Their new treatment for hereditary angioedema, a condition that ... Read more
UnitedHealth Surpasses Quarterly Expectations and Raises Profit Outlook Amid Rising Medical Costs
UnitedHealth Group recently announced impressive first-quarter earnings, surpassing expectations and raising its profit outlook for 2026. The company, which is ... Read more
Revolution Medicines’ Promising Pancreatic Cancer Drug Achieves Success in Late-Stage Trials: A Game Changer in Treatment?
Pancreatic cancer is a serious illness with a very low survival rate of just 13% over five years. However, recent ... Read more
Why Menstrual Product Prices Are Soaring: Understanding Inflation and Tariff Impacts on Your Wallet
Rising prices are affecting everyday products, including menstrual items, highlighting the challenges many face in managing basic needs. Since 2020, ... Read more
Eli Lilly’s Breakthrough Obesity Drug Retatrutide Triumphs in First Late-Stage Diabetes Trial: What It Means for You
Eli Lilly is making waves with its new obesity drug, retatrutide. Recently, it passed a critical late-stage trial focusing on ... Read more
Why Stopping GLP-1 Medications Could Increase Your Risk of Heart Attack, Stroke, and Death: Key Insights from New Study
GLP-1 drugs are making waves in healthcare. About 1 in 8 adults in the U.S. currently use them for weight ... Read more
Eli Lilly Unveils Innovative Zepbound: One Pen, One Month’s Supply – Revolutionizing Obesity Treatment!
Eli Lilly recently launched an exciting new version of its popular obesity drug, Zepbound. This new version comes in a ... Read more
Novo Nordisk Shares Drop 15% as Weight Loss Drug Fails to Compete with Eli Lilly’s Breakthrough in Latest Trial
Novo Nordisk’s stock dropped by 15% on Monday after news that its weight-loss drug, CagriSema, did not meet its main ... Read more
Unlock Savings: Everything You Need to Know About Trump Rx, the White House’s New Direct-to-Consumer Drug Portal
President Trump will soon unveil TrumpRx, a new website aimed at lowering prescription drug costs for Americans. This initiative focuses ... Read more
